Article
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
Hepatology (Baltimore, Md.) - 1 Mar 2012
Zeuzem Stefan, Buggisch Peter, Agarwal Kosh, Marcellin Patrick, Sereni Daniel, Klinker Hartwig, Moreno Christophe, Zarski Jean-Pierre, Horsmans Yves, Mo Hongmei, Arterburn Sarah, Knox Steven, Oldach David, McHutchison John G, Manns Michael P, Foster Graham R
Abstract excerpt
UNLABELLED: Tegobuvir (GS-9190), a non-nucleoside nonstructural protein (NS)5B polymerase inhibitor, and GS-9256, an NS3 serine protease inhibitor, individually have activity against hepatitis C virus (HCV) genotype 1. The antiviral activity of tegobuvir and GS-9256 as oral combination therapy, or together with ribavirin (RBV) or pegylated interferon (Peg-IFN) alpha-2a and RBV, was assessed in a phase II,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.